A B S T R A C T Blood glucose, glucose tolerance, serum insulin, free fatty acids in serum, plasma noradrenaline, and plasma adrenaline were measured in 10 patients with acute myocardial infarction (AMI) as well as in healthy subjects. Both noradrenaline and adrenaline in plasma were elevated in patients with AMI, the level being fairly constant in the individual patients and dependent on their degree of illness.
tients with AMI, especially in patients with high plasma noradrenaline and a low initial rise in insulin. There was a significant negative correlation between the initial rise in insulin expressed in percentage of the basal insulin concentration and the plasma noradrenaline level.
The statistical effects of serum insulin and plasma noradrenaline on the glucose tolerance could not be separated from each other. The decline in free fatty acids after intravenous injection of glucose showed a negative correlation with plasma noradrenaline and a positive correlation with the initial rise in insulin.
Plasma adrenaline did not correlate with any of the metabolic parameters mentioned above.
The plasma noradrenaline concentration was elevated to such a degree in patients with AMI that the observed changes in metabolism might have been caused directly by the circulating noradrenaline.
During the glucose tolerance tests, the effect of noradrenaline was probably carried out indirectly via a suppression of insulin secretion. It is conceivable that
INTRODUCTION
It is generally accepted that the activity of the adrenergic system is increased in patients with acute myocardial infarction (AMI) .' Plasma catecholamine concentration is elevated and in the individual patient the level is fairly constant during the first 2 days after admission to hospital. The level may vary considerably in different patients and is dependent upon their degree of illness (1, 2) .
Most patients with AMI show a diabetes-like change in metabolism. Glucose tolerance is impaired (3-7) and free fatty acids are raised (5, 8, 9) . Less consistent results have been reported for plasma insulin (4, 5, 7, 10 ). An increased adrenergic activity is often assumed to be at least partially responsible for the altered metabolic state.
Very little information is available about the relationship between the degree of augmented adrenergic activity and blood glucose concentration, serum insulin, and free fatty acids (FFA) in patients with AMI. The best way of estimating adrenergic activity is probably by measuring the concentration of noradrenaline and adrenaline in plasma. Previously it had been very difficult or impossible to obtain reliable measurements of circulating catecholamines by the various fluorimetric methods. However, this problem has been overcome by the introduction of a sensitive and precise double-isotope derivative technique for the determination of noradrenaline and adrenaline (11) (12) (13) .
In the present study plasma noradrenaline and plasma adrenaline were measured in 10 patients with AMI, 
METHODS
Subjects. 10 patients, admitted to a coronary care unit within 12 h after onset of precordial pain, were studied. All of them had unequivocal signs of recent transmural myocardial infarction in electrocardiogram and enzyme analyses. Four patients had anterior wall infarctions, one an anteroseptal, and five posterior wall infarctions. None of the patients had known diabetes mellitus or hypertension and none were taking drugs known to influence the sympathetic nervous system.
After admission to hospital, all patients received an injection of an analgesic drug. The dose was repeated later on if necessary. Digitalization was started in three patients. Shortly after their admission to hospital, two patients received lignocaine as intravenous bolus injection due to multiple ventricular ectopic beats. No patients received intravenous glucose infusion or heparin before the glucose tolerance test.
A degree of illness index in the individual patient was calculated as described previously (1) . In addition the degree of illness was also evaluated with the coronary prognostic index described by Norris, Brandt, Caughey, Lee, and Scott (14) . Four patients were reexamined 3 mo after their discharge from hospital.
Plasma catecholamine concentrations in control subjects admitted to a coronary care unit with precordial pain but without evidence of cardiovascular disease have been presented elsewhere (1). However, an additional five normal subjects were examined with special reference to their metabolic responses.
Procedure. Venous blood was collected from the superior vena cava via an indwelling catheter while the patients rested in the recumbent position. Samples were obtained shortly after the patients were admitted to hospital, after overnight fasting, and during an intravenous glucose tolerance test.
25 g of glucose was injected intravenously over 4 min. Blood was collected at 2-min intervals, calculated from the midpoint of the injection, until 10 min had elapsed and thereafter at 20, 30, 40, and 60 min after the glucose injection. The glucose tolerance was assessed as the rate of disappearance of glucose f rom the blood, measured as the slope of the glucose curve plotted on semilogarithmic paper against time (K = (ln 2/ti) X 100). A K value for the fall of serum free fatty acids during the i.v. glucose tolerance test was calculated in the same way.
Blood glucose, serum insulin, and FFA in serum were measured in each of the above-mentioned samples, including two samples obtained shortly after the patients' admission to hospital, as well as two samples obtained after overnight fasting, just before the injection of glucose. Plasma noradrenaline and plasma adrenaline were measured after admission (two samples), after overnight fasting (two samples), and 10, 30, and 60 min after i.v. injection of glucose.
The normal subjects were studied after overnight fasting. Blood samples were obtained before and after intravenous injection of 25 g of glucose, as described for the patients with AMI.
To study the influence of the blood sampling site on the plasma catecholamine concentration, blood was also collected from the brachial artery in one patient with AMI. Blood samples were collected from various sites in one normal subject in whom high plasma catecholamine levels had been induced by strenuous exercise.
An informed consent to the procedure was obtained from all subjects studied.
Conventional probability levels of significance were used in the statistical analysis, and a P value greater than 0.05 was considered nonsignificant. The t test was used for testing the significance of differences between mean values. Regression analysis was performed according to Bailey (15) .
Analyses. Plasma noradrenaline and plasma adrenaline were measured by the double-isotope derivative technique described by Engelman and Portnoy (11), except for some minor modifications. Results of recovery experiments and other methodological data have been presented elsewhere (13) . Approximately 4-5 ml of plasma was used in each analysis.
Glucose concentration in whole blood was measured by a glucose oxidase method (16) . FFA in serum were measured by a modification of Dole's titrimetric method (17) . Plasma insulin was measured by wick chromatography (18) .
RESULTS
Pertinent clinical data in the 10 patients with AMI and in the normal subjects are given in Table I . Mean values of the measured parameters are given in Table  II . Pertinent laboratory data in each individual patient with AMI are given in Table III . In the individual patient, the plasma noradrenaline and adrenaline concentrations were very similar at admission to hospital, after fasting, and during the intravenous glucose tolerance test. The five mean values did not differ significantly from each other. The mean noradrenaline and adrenaline concentration during the glucose tolerance test was calculated for each person and used for further analysis (NaGt) . The mean plasma catecholamine concentration varied considerably among the different patients and correlated with their degree of illness (P less than 0.05). The mean plasma noradrenaline and adrenaline concentration was significantly higher in patients with AMI than in the five normal subjects (P less than 0.02, 0.001). The catecholamine values were also higher than those obtained in a group of patients admitted to the coronary care unit with chest pain but without evidence of cardiovascular disease (1) (P less than 0.02). 7 of the 10 patients with AMI had mean plasma noradrenaline values exceeding the calculated upper 95% limit of the values obtained in the controls. The plasma adrenaline concentration was not correlated with the plasma noradrenaline concentration. Furthermore plasma adrenaline was not correlated with any of the metabolic parameters mentioned below and will not be considered in detail in the following. However, a correlation was observed between the adrenaline concentration during fasting and after intravenous injection of glucose in the individual patients with AMI (P less than 0.05). Blood glucose concentrations are given in Table II and III. There was a highly significant correlation between the fasting glucose concentration and plasma noradrenaline after overnight fast (Na-Fa) in patients with AMI (P less than 0.001, Fig. 1 ). In one patient a blood sample was not available for estimation of the fasting glucose concentration. The mean fasting glucose concentration in patients with AMI and elevated plasma noradrenaline was significantly higher than in the control subjects (P less than 0.01).
The glucose K value varied between 2.04 and 0.64 in patients with AMI. There was a significant correlation between the log K value and plasma Na-Gt (P less than 0.01, Fig. 2 ). The mean K value in patients with AMI and elevated plasma noradrenaline was significantly lower than the K value in the controls (P less than 0.05). There was a strong correlation between the glucose K value and the insulin index (P less than 0.001, Fig. 3 ) and between log insulin index and the plasma Na-Gt (P less than 0.005, Fig. 4 ). Significant results were also obtained when the absolute insulin values were used in the statistical analysis; however, the level of significance was much lower (P less than 0.05).
Multiple regression analysis was carried out with the log K value as the dependent variable and the log insulin index and the plasma Na-Gt concentration as the two independent variables. This analysis showed that the statistical effect of the insulin index and plasma Na-Gt on the K value could not be separated from each other and both became insignificant. This means that in the individual patient with AMI a low glucose K value was combined with a low insulin index and a high plasma noradrenaline concentration. A high K value was combined with a high insulin index and a low plasma noradrenaline level.
The mean rise in insulin in patients with AMI and elevated plasma noradrenaline was 20 gU/ml and the corresponding value in the controls 46 dU/ml (P less than 0.05). The mean insulin index in patients with AMI and elevated plasma noradrenaline was 1.1, significantly lower than the corresponding value of 3.9 in the controls (P less than 0.01).
The concentration of FFA in serum is given in Table   II coefficients were significant (P less than 0.05 in both cases).
The equation of the regression line is:
z (log FFA Aeq/liter) =-0.0123 (insulin AU/ml) + 0.1727 (Na-Fa ng/ml) + 2.947
The rate of fall in FFA in serum after intravenous injection of glucose was expressed like the glucose K value. The FFA K value was correlated with the insulin index (P less than 0.05, Fig. 5 ) and with the plasma Na-Gt (P less than 0.05, Fig. 6 ). By multiple regression analysis with the FFA K value as the dependent variable and the insulin index and the plasma Na-Gt as the two independent variables, both partial regression coefficients became insignificant, indicating that a low K value, a low insulin index, and a high plasma Na-Gt were combined in the individual patient, and vice versa. the corresponding value of 3.8 in the control subjects (P less than 0.01).
Unfortunately only 4 of the 10 patients with AMI could be re-examined. The data are given in Table IV . Mean fasting insulin concentration was approximately halved at the second examination, but the difference was not significant. In two of the patients, 3 and 5, the other parameters were rather unchanged. Both of these subjects had normal plasma catecholamine concentrations during AMI. In the two other subjects, 8 and 10, with high noradrenaline values at the initial examination the rise in insulin after intravenous glucose was doubled, the insulin index increased, the glucose K value improved and the fasting glucose concentration lower at the second examination. Plasma noradrenaline concentration was now normal for their age. The improvement in glu- cose tolerance in patients 8 and 10 was not larger than could be expected from the rise in the insulin index (Fig. 3) . 
DISCUSSION
Patients with AMI show a transitory hyperglycemia. There are, however, conflicting data about the duration of the hyperglycemia (3-6). Lebovitz (4, 19) but an early rise after glucose administration has been observed. Plasma cortisol is elevated especially in patients with complications (20) (21) (22) (23) (24) .
Plasma glucagon has also been found to be elevated (25) .
The initial metabolic alterations in patients with AMI have been related to an increased adrenergic activity, especially an increased adrenaline secretion (4, 5, 10, 26) . Oliver (26) considered the rise in FFA to be due to an increased noradrenaline secretion and a relationship between FFA and plasma noradrenaline has been reported (27, 28) .
The present study indicates, however, that elevated plasma adrenaline concentrations were not the cause of the altered metabolic state in patients with AMI. Plasma adrenaline did not correlate with any of the measured metabolic parameters.
Highly significant correlations were observed between plasma noradrenaline and the fasting glucose concentration, the glucose tolerance, and the insulin index and a weaker but significant correlation was obtained with the rate of fall of FFA after i.v. injection of glucose.
Na-Fa was correlated to fasting FFA only after the varying insulin levels had been taken into account. The important question is whether the observed statistical correlations between plasma noradrenaline and the other metabolic parameters indicate a causal relationship. Both factors (e.g., plasma noradrenaline and the insulin index) could simply reflect different degrees of severity of the disease in the individual patients, rather than being causally related to each other. The metabolic and circulatory situation in patients with AMI is so complicated that plasma noradrenaline cannot be interpreted in terms of sympathetic nervous activity in different organs, or be divided into a metabolic and circulatory component. It appears, however, that the plasma noradrenaline concentration is so high in many patients with AMI that a major metabolic effect may well occur as a result of the circulatory noradrenaline per se. The highest plasma noradrenaline concentration observed in the present study was just above 2 ng/ml. According to Cohen Lebovitz et al (4) observed a hyperinsulinemic response to i.v. glucose in patients with AMI 6-14 days after the patients were admitted to hospital. At a later examination the insulin response was lower but the glucose tolerance unchanged, indicating a period of insulin antagonism occurring between days 6 and 14. In the present study a decreased insulin reponse to glucose, rather than insulin antagonism, characterized the metabolic situation in the initial period after AMI. It is conceivable that insulin antagonism is a milder and therefore often a later-appearing stress phenomenon (34, 35) . It should be emphasized that the use of the insulin index in the statistical analysis rather than of the absolute insulin values tends to eliminate any effect of insulin antagonism. It is obvious that in the patients with AMI, the insulin index was more reduced than the absolute insulin values.
